INTRODUCTION
============

Desmoid tumor, also known as aggressive fibromatosis, is a rare, locally invasive, nonmetastasizing but potentially multifocal proliferation of mesenchymal stem cell progenitors \[[@R1]\]. Desmoid tumors constitute a soft tissue mass arising at any part of the body in different types of connective tissues, including muscle, fascia, and aponeurosis. The most common primary sites are the abdominal wall, limbs, girdles, and mesenteric area. Desmoid tumors infiltrate the surrounding structures and spread along planes and muscle. Desmoid tumors can lead to severe pain, functional impairment and, more rarely, a life-threatening condition. Desmoid tumors are typically diagnosed in young adults (peak incidence at 35--40 years), mainly in women at reproductive age \[[@R2]^▪▪^\]. The course of desmoid tumor is unpredictable, as spontaneous regression, long-lasting stable disease and disease progression can occur, and reliable and validated predictive factors are lacking. Desmoid tumors comprise at least two different clinico-pathological entities: sporadic desmoid tumor and desmoid tumor associated with germline mutation of *APC*. Here, we aim to summarize the most recent data about the biology and management of adult desmoid tumor as well as to describe the current ongoing clinical trials. 
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CLINICO-PATHOLOGICAL ENTITIES
=============================

The two entities (sporadic desmoid tumor vs. desmoid tumor associated with *APC* mutation) are associated with specific mutually exclusive molecular alterations (*CTNNB1* mutation in sporadic desmoid tumor vs *APC* mutation in desmoid tumor with germline mutation of *APC*) \[[@R3]--[@R5],[@R6]^▪▪^\]. Because no other alteration has been identified as recurrent by whole-exome sequencing and genomic analysis, these Wnt/APC/β-catenin pathway alterations are considered to be the driver of tumor cell proliferation.

Sporadic desmoid tumor
----------------------

The *CTNNB1* gene encodes for β-catenin, a proto-oncogene. β-Catenin regulates cell adhesion and cell transcription. In desmoid tumor, there is an abnormal stabilization and nuclear accumulation of β-catenin. The accumulated β-catenin binds *transducin beta-like protein* 1 (TBL1/TBLR1), and this complex stimulates the expression of several Wnt/APC/β-catenin pathway target genes, including some proliferative factors, such as *S100A4* or *CTHRC1*\[[@R4]\]. Three major mutation hotspots have been described in *CTNNB1* exon 3, T41A, S45F, and S45P \[[@R5],[@R6]^▪▪^\]. These hotspots affect the site of APC/β-catenin interaction and alter the ability of APC to drive β-catenin degradation by the proteasome \[[@R4]\].

Most desmoid tumors (85--90%) are sporadic and associated with somatic *CTNNB1* mutations \[[@R7]--[@R9]\]. In sporadic desmoid tumor, a female predominance is obvious (sex ratio of approximately 0.5), and the median age at diagnosis is approximately 40 \[[@R2]^▪▪^\]. In the largest series of sporadic desmoid tumor (*n* = 254), 88% had *CTNNB1* mutations identified by direct sequencing, whereas no mutations were detected in 175 potential morphologic mimics \[[@R8]\]. The most common *CTNNB1* mutations are T41A (approximately 55%), S45F (approximately 35%), and S45P (approximately 10%) \[[@R6]^▪▪^,[@R10]\]. Rarer mutations or deletions have been described \[[@R6]^▪▪^,[@R10]\]. Interestingly, Doyen *et al.*\[[@R11]\] recently reported 2 cases of patients with multiple metachronous sporadic desmoid tumor associated with distinct *CTNNB1* mutations.

Desmoid tumor associated with germline *APC* mutations
------------------------------------------------------

In cases of FAP, a truncated APC protein with low affinity to β-catenin is created. This process results in the nuclear accumulation of β-catenin and, consequently, the deleterious overexpression of its target genes \[[@R4]\].

Approximately 10--15% of desmoid tumors are associated with germline mutations of *APC*, providing different syndromic associations: desmoid tumor associated with FAP, desmoid tumor as part of Gardner syndrome (FAP, desmoid tumor, and osteomatosis of the skull and the mandible, sebaceous cysts, and cutaneous and subcutaneous fibromas) or desmoid tumor associated with Turcot syndrome (FAP and brain tumor) \[[@R12]\]. Here, the sex ratio is close to 1 \[[@R13]--[@R15]\].

A meta-analysis of five European FAP registries (2260 patients and 912 families) showed that the occurrence of desmoid tumor is approximately 10% (220/2260), the median age at diagnosis is 31 years, and the first desmoid tumors are often in the intra-abdominal space (52.9%) or abdominal wall (24.6%) \[[@R15]\]. Desmoid tumor is diagnosed after prophylactic surgery in 72.0% of cases and before surgery in 28.0%. The median time between prophylactic surgery and the diagnosis of desmoid tumor was 36 months (range, ref). The *APC* mutation is located beyond codon 1444 in 65.0% of cases associated with DT. Risk factors for desmoid tumor in univariate analysis are *APC* mutation beyond codon 1444 (*P* \< 0.0001), age at first surgery less than 31 years (*P* = 0.003), and prior abdominal surgery (*P* = 0.003). In multivariate analysis, the *APC* mutation site (OR = 3.0, *P* \< 0.0001) and prior surgery (OR = 2.58, *P* = 0.0004) were the two independent risk factors for desmoid tumor \[[@R15]\].

Other studies confirm that compared to other mutations, *APC* mutation beyond codon 1444 is a significant risk factor for desmoid tumor \[[@R16]--[@R18]\]. Prior familial history of desmoid tumor is a risk factor for desmoid tumor, but this phenotype probably reflects the underlying germline mutation \[[@R19]\].

Desmoid tumors are a major concern in FAP patients and cause significant morbidity and mortality, as most cases are intra-abdominal (in the small bowel mesentery) and can cause bowel obstruction or ulceration and ureter stenosis. Desmoid tumor was the main cause of death in some series of patients with FAP with desmoid tumor \[[@R13]\].

FAP requires prophylactic colectomy to reduce recto-colic cancer mortality. However, this necessary surgical procedure plays a key role in the initiation and promotion of desmoid tumor. Regarding these facts, the appropriate surgical procedure (ileorectal anastomosis vs. proctectomy) is debated \[[@R14]\]. On one hand, some authors suggest that proctectomy is a simple procedure that avoids the risk of re-operation, which could increase the occurrence of desmoid tumor. On the other hand, some authors claim that FAP associated with desmoid tumor is usually an attenuated form that does not require rectum ablation and is accessible for careful follow-up of the remaining rectum \[[@R20]\]. In the international study mentioned above, the type of prophylactic surgery was not a risk factor for desmoid tumor occurrence (*P* = 0.53) \[[@R15]\]. Ultimately, the issue of the ideal prophylactic surgical procedure is still an open question.

'Wild-type' desmoid tumor
-------------------------

*CTNNB1* or *APC* mutations are mutually exclusive and nearly universal in desmoid tumor; in a series of 117 cases, Crago *et al.* found mutation of *CTNNB1* in 101 cases and mutation of *APC* in 10 cases, as well as other gene alterations affecting the *Wnt*/APC/*β-catenin* pathway, including chromosome 6 loss (two cases) and *BMI1* mutation (one case) \[[@R6]^▪▪^\]. Ultimately, the so-called 'wild-type' desmoid tumor (without *CTNNB1* or *APC* mutations) does not exist, or is misdiagnosed (other spindle cell proliferation mimicking desmoid tumor) \[[@R2]^▪▪^,[@R8]\] or desmoid tumor with *CTNNB1* or *APC* mutations unrecognized by nonsensitive standard diagnostic methods \[[@R6]^▪▪^\], and exceptional desmoid tumor with other molecular alterations of the Wnt/APC/β-catenin pathway \[[@R6]^▪▪^\].

MANAGEMENT OF DESMOID TUMOR
===========================

Diagnosis
---------

Magnetic resonance imaging (MRI) is regarded as the most appropriate imaging method to better characterize the initial extension of desmoid tumor and to monitor the outcome \[[@R21]\]. Imaging-guided core-needle biopsy is required to formally diagnose desmoid tumor. However, mesenteric masses could be difficult or hazardous to biopsy. Histologically, DTs are composed of monoclonal spindle-shaped cells separated by an abundant collagenous matrix. A French nationwide survey demonstrated that one-third of desmoid tumors are misdiagnosed (the most challenging differential diagnoses are nodular fasciitis and low grade fibromyxoid sarcoma) \[[@R2]^▪▪^\]. A second opinion by an expert pathologist is of major importance in such diseases \[[@R2]^▪▪^\]. The nuclear overexpression of β-catenin is a useful diagnostic tool, but its sensitivity depends on the immunohistochemistry method used. We strongly believe that a second opinion by an expert pathologist is necessary.

There is no consensus on initial rectocolonoscopy in the initial work-up of desmoid tumor. Desmoid tumor could be the first manifestation of FAP (initial germline mutation or unrecognized inherited mutation in cases of attenuated FAP). Thus, initial rectocolonoscopy could be considered. Nevertheless, because *APC* and *CTNNB1* mutations appear to be mutually exclusive, rectocolonoscopy could be avoided in cases with a desmoid tumor harboring somatic mutations of *CTNNB1*.

Treatment
---------

The multidisciplinary management of desmoid tumor requires cautious assessment of the expected benefits and risks associated with the proposed treatment; ideally, it is a decision shared with the patient.

Large en-bloc surgery is no longer regarded as the cornerstone treatment for desmoid tumor because the rate of relapse after surgery exceeds 60% in larger series \[[@R22]\]. The risk of relapse is similar in the context of *APC* germline mutations (approximately 22/42) \[[@R13]\]. The local relapse could be larger than the primary tumor. Some clinical parameters are associated with a high risk of relapse after surgery in different studies; these parameters include young age \[[@R22],[@R23]\], large tumor size \[[@R22]--[@R24]\], and positive margins \[[@R22],[@R24]\]. Crago *et al.*\[[@R22]\] developed and then validated a predictive nomogram based on age, tumor size and primary location. Several studies suggest that the S45F *CTNNB1* mutation is an important risk factor for local recurrence after curative-intent surgery for primary desmoid tumor (Table [1](#T1){ref-type="table"}) \[[@R25]--[@R29]\]. Salas *et al.*\[[@R30]\] developed a 36-gene molecular signature that predicted relapse after surgery with an accuracy of 78%. In this model, the top two genes that were upregulated in the recurrence group were FECH (*ferrochelatase,* which is involved in protoheme biosynthesis) and stomatin-like protein 2, which regulates mitochondrial functions. The top gene upregulated in the no recurrence group was thyroid hormone receptor-interacting protein 6, which is involved in cell adhesion.

###### 

The S45F mutation as a risk factor for local relapse after surgery for primary desmoid tumor

  n     Median follow-up (months)   Relapse, *n* (%)   S45F mutation, *n* (%)   S45F as a risk factor   Ref.                 
  ----- --------------------------- ------------------ ------------------------ ----------------------- -------------------- ------------
  89    62                          Not done           19 (21.3)                4.28 (1.75--10.48)      4.28 (1.75--10.48)   \[[@R26]\]
  179   50                          48 (26.8)          39 (21.7)                Not done                2.59 (1.19--5.65)    \[[@R27]\]
  101   Not done                    50 (49.5)          37 (36.6)                Not done                Not done             \[[@R28]\]
  95    31                          Not done           23 (24.2)                Not done                Not done             \[[@R29]\]
  101   41                          17 (16.8)          18 (17.8)                8.50 (1.85--39.00)      6.20 (2.24--17.15)   \[[@R30]\]

Other parameters included in the multivariate models: young age \[[@R30]\]; sex, R0 resection, tumor size, and tumor location \[[@R27]\]; no other significant prognosticator \[[@R27]\].

Therefore, there has been a shift to a more conservative approach, the 'wait-and-see' policy \[[@R31]\]. Currently available data suggest that only a small percentage of desmoid tumors are progressive and that most progressions are seen within 36 months following diagnosis \[[@R23],[@R32],[@R33]\]. French and Italian studies suggest that the 'wait and see' policy is well tolerated, particularly in cases of sporadic abdominal wall desmoid tumor (Table [2](#T2){ref-type="table"}) \[[@R23],[@R32],[@R34]\]. This approach has been assessed by different prospective trials. It has been recommended by several authors and has been proposed as the standard of care, at least in Europe \[[@R35]\]. The 'wait and see' policy avoids inadequate treatment for desmoid tumor that could spontaneously regress and discourages treatment for stable and pauci-symptomatic desmoid tumor. Reasons for treatment (including surgery) are volumetric progression and symptom worsening. However, the precise definition of the population of patients which should be proposed for watch and wait is missing.

###### 

Sporadic desmoid tumor: 'wait and see' experiences

  *n*   Abdominal wall DT, *N* (%)   Median follow-up (months)   Spontaneous regression, *n* (%)   Secondary surgery, *n* (%)   Requiring systemic treatment, *n* (%)   Ref.
  ----- ---------------------------- --------------------------- --------------------------------- ---------------------------- --------------------------------------- ------------
  106   102 (100)                    31                          29 (28.4)                         15 (14.1)                    22 (20.7)                               \[[@R32]\]
  27    Not done                     52                          5 (18.4)                          Not done                     Not done                                \[[@R23]\]
  70    70 (100)                     39                          Not done                          3 (4.2)                      22 (31.4)                               \[[@R35]\]

Radiotherapy is rarely used in desmoid tumor management. Adjuvant radiotherapy is proposed in cases of R1/R2 resection and in cases located at critical sites, without demonstration of its utility. Nevertheless, regarding the young age of these patients, close follow-up is preferred because of the potential long-term toxicity of radiotherapy, especially when tumors develop in irradiated fields. Radiotherapy at a dose of 56 Gy in 28 daily fractions of 2 Gy has been shown to provide adequate local control in the vast majority of progressive patients, with a local control rate of 77% and a complete response rate of 17% \[[@R36]\]. Long-term follow-up is required to better analyze the risk\--benefit ratio of this option \[[@R36]\]. Other local procedures could be discussed in locally advanced and progressive desmoid tumor: cryoablation and isolated limb perfusion \[[@R37]\].

Different systemic treatments could be used in cases of desmoid tumor progression (Table [3](#T3){ref-type="table"}) \[[@R21],[@R37]--[@R45]\]. Today, none of these treatments could be considered as a standard of care, as available data have only come from retrospective studies with a limited number of cases or nonrandomized phase II studies. A large retrospective case series (*n* = 134) showed that 85% of patients with desmoid tumor treated with antiestrogen achieve progression arrest. This rate is similar in sporadic desmoid tumor and FAP-associated desmoid tumor \[[@R47]\]. Some authors regard anthracycline-based regimens as those providing a higher objective response rate (approximately 50%); however, the available data are scarce (Table [3](#T3){ref-type="table"}). A phase II trial assessing the activity of the methotrexate-vinblastine is very interesting because it showed that approximately 60% of patients experience symptom palliation, and the long-term efficacy was impressive (10-year progression-free survival of approximately 60%) \[[@R40]\]. Tyrosine kinase inhibitors have shown some signs of activity (Table [3](#T3){ref-type="table"}). However, overall, in the absence of an internal control or randomization, it is difficult to attribute the observed slowing of tumor progression to the natural history of the disease or to the real activity of systemic treatment. Currently, there is no reliable tool for choosing the best systemic treatment in progressive desmoid tumor. However, some studies suggest that desmoid tumors harboring *CTTNB1* mutations are more sensitive to imatinib than desmoid tumors without *CTTNB1* mutations \[[@R44]\], and the *CTTNB1* S45F mutation is associated with resistance to NSAIDs (meloxicam) compared to other mutations or the absence of mutations (4/4 vs. 9/29) \[[@R48]\]. Further clinical trials are urgently needed to identify predictive factors and properly assess the activity of the treatment using randomized trials and trials using quality of life data.

###### 

Systemic therapy options in adults with desmoid tumors: 'best available' evidence

  Treatment                   Nature of the study   *n*   Objective response rate   Other activity endpoints   Ref.
  --------------------------- --------------------- ----- ------------------------- -------------------------- ------------
  Sulindac                    Retrospective         14    57%                                                  \[[@R38]\]
  Toremifene                  Retrospective         27    22%                       6-month PFS: 76%           \[[@R39]\]
  Methotrexate-Vinblastine    Phase II              27    15%                       10-year PFS: 67%           \[[@R40]\]
  Pegylated doxorubicin       Retrospective         14    33%                                                  \[[@R41]\]
  Doxorubicin + dacarbazine   Retrospective         12    50%                                                  \[[@R42]\]
  Imatinib (800 mg/day)       Phase II              51    6%                        1-year PFS: 66%            \[[@R43]\]
  Imatinib (800 mg/day)       Phase II              37    3%                        6-month PFS: 65%           \[[@R44]\]
  Imatinib (400 mg/day)       Phase II              50    12%                       1-year PFS: 67%            \[[@R45]\]
  Sunitinib                   Phase II              19    26%                       1-year PFS: 80%            \[[@R46]\]
  Sorafenib                   Retrospective         26    26%                                                  \[[@R21]\]

PFS, progression-free survival.

Supportive care
---------------

Pain management is a major issue for patients with DT. In a limited case series (*n* = 16), Emori *et al.*\[[@R49]\] showed that desmoid tumor-related pain is associated with the overexpression of cyclooxygenase-2. Patients affected by desmoid tumor are young and will face long-lasting morbidity; therefore, functional impairments must be managed by physiotherapists and social workers to avoid work and social exclusion. Supportive care is of major importance in this condition.

Pregnancy is another complex issue for women with sporadic desmoid tumor. We know that a large number of cases occur within the 24 months following pregnancy; these cases typically arise in the abdominal wall. This observation suggests that hormone signaling, mechanical constraints, inherent trauma, or postpartum healing play a role in the development of desmoid tumor \[[@R50]\]. A large multicenter retrospective study of cases diagnosed during pregnancy provided the following evidence: the probability of spontaneous regression after pregnancy was approximately 10%, the documented progression after the 'wait and see' policy was 60%, the failure of medical treatment occurred in 10%, and the risk of relapse after surgery was 13% \[[@R50]\]. In patients with preexisting desmoid tumor, the occurrence of pregnancy was associated with a risk of relapse or progression of approximately 40%; this relapse/progression spontaneously regressed in approximately 10% of cases, and medical therapy was effective in approximately 90% of cases \[[@R50]\]. Furthermore, no major obstetric complications (spontaneous vaginal delivery in most cases) were documented in this large retrospective series of cases managed in the reference centers. Ultimately, desmoid tumor cannot be regarded as a definitive contraindication to pregnancy; pregnancy and desmoid tumor can be safely managed in reference centers, when the patient is fully informed of the state of the art regarding the impact of pregnancy on her condition. No recommendations could be made for cases of mesenteric desmoid tumor associated with FAP. Furthermore, in the absence of reliable data, there was no recommendation for hormonal contraceptive treatments or the hormonal treatment of infertility.

FUTURE DIRECTIONS
=================

Ongoing trials are summarized in SDC1 (online appendix). Furthermore, 2 investigational drugs targeting β-catenin are of major interest: tegatrabetan (BC-2059) and the gamma-secretase inhibitor PF-03084014. *In vitro*, tegatrabetan directly stimulates β-catenin degradation. In culture, tegatrabetan induces the apoptosis of desmoid tumor cells. A phase I/II trial is planned. The gamma-secretase inhibitor PF-03084014 stimulates the Notch pathway, which interacts with and indirectly regulates the Wnt/APC/β-catenin pathway. A phase I trial showed a high rate of objective responses among patients with desmoid tumor (five of seven) \[[@R51]\]. A phase II trial is ongoing (SDC1, online appendix).

CONCLUSION
==========

Factors influencing the outcome of desmoid tumor remain unknown. Reliable and validated predictive and prognostic factors have not yet been identified. Desmoid tumors are misdiagnosed in a large number of outside reference centers. Surgery is no longer regarded as the standard of care, and the 'wait and see' policy seems well tolerated, at least in sporadic abdominal wall desmoid tumor. There is no consensus on treatment in cases of progressive desmoid tumor. At least 2 new investigational drugs targeting the Wnt/APC/β-catenin pathway are currently being developed.
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